These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36995386)

  • 21. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
    Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
    NEJM Evid; 2022 May; 1(5):EVIDoa2100066. PubMed ID: 38319212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.
    Sorrenti B; Laurini C; Bosco L; Strano CMM; Scarlato M; Gastaldi M; Filippi M; Previtali SC; Falzone YM
    Eur J Neurol; 2024 Jul; 31(7):e16306. PubMed ID: 38716750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Juvenile Myasthenia Gravis.
    O'Connell K; Ramdas S; Palace J
    Front Neurol; 2020; 11():743. PubMed ID: 32793107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review of Disease Mechanisms and Current and Emerging Treatment Options for Generalized Myasthenia Gravis.
    Bril V; Silvestri NJ; Barnett-Tapia C
    Prim Care Companion CNS Disord; 2022 May; 24(3):. PubMed ID: 35621832
    [No Abstract]   [Full Text] [Related]  

  • 25. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    Saccà F; Barnett C; Vu T; Peric S; Phillips GA; Zhao S; Qi CZ; Gelinas D; Chiroli S; Verschuuren JJGM
    J Neurol; 2023 Apr; 270(4):2096-2105. PubMed ID: 36598575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Clinical Course and Treatment of a Case of Refractory Systemic Juvenile Myasthenia Gravis Successfully Treated with Thymectomy.
    Shibuya M; Shichiji M; Ikeda M; Kodama K; Miyabayashi T; Sato R; Okubo Y; Endo W; Inui T; Togashi N; Nagao M; Sato K; Sato T; Kanzaki M; Segawa O; Masui K; Ishigaki K; Haginoya K
    Tohoku J Exp Med; 2024 Jan; 262(1):29-31. PubMed ID: 37967941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
    Dos Santos JBR; Gomes RM; da Silva MRR
    Expert Rev Clin Immunol; 2022 Sep; 18(9):879-888. PubMed ID: 35892247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporal correlation between serum CH
    Yanagidaira M; Nishida Y; Yokota T
    Clin Neurol Neurosurg; 2020 Feb; 189():105630. PubMed ID: 31830679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis.
    Dalakas MC
    Expert Rev Clin Immunol; 2022 Jul; 18(7):691-701. PubMed ID: 35730504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
    Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
    Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Starting eculizumab as rescue therapy in refractory myasthenic crisis.
    Vinciguerra C; Bevilacqua L; Toriello A; Iovino A; Piscosquito G; Calicchio G; Barone P
    Neurol Sci; 2023 Oct; 44(10):3707-3709. PubMed ID: 37306795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eculizumab for the treatment of myasthenia gravis.
    Mantegazza R; Cavalcante P
    Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fc-Receptor Targeted Therapies for the Treatment of
    Keller CW; Pawlitzki M; Wiendl H; Lünemann JD
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071155
    [No Abstract]   [Full Text] [Related]  

  • 39. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.
    Vanoli F; Mantegazza R
    Neurotherapeutics; 2022 Apr; 19(3):897-910. PubMed ID: 35165857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.